Expert Insights

Patrick Neven, MD, PhD, discusses updated phase 1b results from the CAPItello-292 study which demonstrated that capivasertib plus palbociclib and fulvestrant was safe and tolerable among heavily pre-treated patients with HR-positive,...

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

Aaron Gerds, MD, examines potential treatment risks for patients with myelofibrosis and how to mitigate them in order to achieve the best possible outcomes.

Aaron Gerds, MD, discusses the phase 3 MOMENTUM trial on momelotinib treatment for patients with myelofibrosis, including those with anemia, which served as the basis for the approval of momelotinib by the US FDA.

Benjamin Lowentritt share results from a study of real-world data which found more patients with metastatic castration-resistant prostate cancer had a deep, early PSA response to apalutamide than enzalutamide.

Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 

During the 2023 Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.